Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response

详细信息    查看全文

• 作者：Fengjuan Wang (1)
  Xiuli Feng (1)
  Qisheng Zheng (2)
  Hongyan Hou (3)
  Ruibing Cao (1)
  Bin Zhou (1)
  Qingtao Liu (4)
  Xiaodong Liu (1)
  Ran Pang (1)
  Jin Zhao (1)
  Wenlei Deng (1)
  Puyan Chen (1)
  
• 关键词：Japanese encephalitis virus ; rMVA ; mep ; Immune response ; Protection response
• 刊名：Virology Journal
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：9
• 期：1
• 全文大小：681KB
• 参考文献：1. Shope RE: Medical significance of togaviruses: an overview of diseases caused by togaviruses in man and in domestic and wild vertebrate animals. In / The togaviruses. Edited by: Schlesinger RW. New York: Academic; 1980:47-2. CrossRef
  2. Monath TP: Pathobiology of the flaviviruses. In / The Togaviridae and Flaviviridae. Edited by: Schlesinger S, Schlesinger MJ. New York: Plenum Press; 1986:375-40. CrossRef
  3. Scherer WF, Moyer J, Izumi T, Gresser I, McCown J: Ecologic studies of Japanese encephalitis virus in Japan: VI, Swine in fection. / AmJTrop Med Hyg 1959, 8:698-06.
  4. Konno J, Endo K, Agatsuma H, Ishida N: Cyclic outbreaks of Japanese encephalitis among pigs and humans. / Am J Epidemiol 1966,84(2):292-00.
  5. Oya A: The role of mammals as primary and supplementary hosts. / Jpn J Med Sci Biol 1967,20(Suppl):26-0.
  6. Vythilingam I, Oda K, Mahadevan S, Abdullah G, Thim CS, Hong CC, Vijayamalar B, Sinniah M, Igarashi A: Abundance, parity, and Japanese encephalitis virus infection of mosquitoes (Diptera: Culicidae) in Sepang District, Malaysia. / J Med Entomol 1997, 34:257-62.
  7. Tsai TF, Chang GF, Yu YX: Japanese encephalitis vaccines. In / Vaccines. 3rd edition. Edited by: Stanley AP, Oreustein WA. Philadelphia, USA: Saunders; 1999:672-10.
  8. Plesner AM: Allergic reactions to Japanese encephalitis vaccine. / Immunol. Allergy Clin. North Am. 2003, 23:665-97. CrossRef
  9. Olszewska W, Steward MW: Nasal delivery of epitope-based vaccines. / Advanced Drug Delivery Reviews 2001, 51:161-71. CrossRef
  10. Kimura-Kiroda J, Yasui K: Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. / J Immunol 1988, 141:3606-610.
  11. Mason PW, Pincus S, Fournier MJ, Masom TL, Shope RE, Paoletli E: Japanese encephalitis virus wmcinia recombinants produce particle form of the structural membrane proteins and induce high levels of protection against lethal JEV infection. / Virology 1991, 180:294-05. CrossRef
  12. Murali-Krishna K: Ravi VR, Manjunath: Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. / J Gen Virol 1996,77(Pt. 4):705-14. CrossRef
  13. Kaur R, Sachdeva G, Vrati S: Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. / J Infect Dis 2002, 185:1-2. CrossRef
  14. Dewasthaly S, Ayachit VM, Sarthi SA, Gore MM: Monoclonal antibody raised against envelope glycoprotein peptide neutralizes Japanese encephalitis virus. / Arch Virol 2001, 146:1427-435. CrossRef
  15. Kolaskar AS, Kulkarni-Kale U: Prediction of three-dimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus. / Virology 1999, 261:31-2. CrossRef
  16. Seif SA, Morita K, Matsuo S, Hasebe F, Igarashi A: Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli-system. / Vaccine 1995, 13:1515-521. CrossRef
  17. Sette A, Fikes J: Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. / Curr Opin Immunol 2003, 15:461-70. CrossRef
  18. Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, Tangri S, Alexander J, Fikes J, Chesnut R: Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. / Tissue Antigens 2002, 59:443-51. CrossRef
  19. Sette A, Livingston B, McKinney D, Appella E, Fikes J, Sidney J, New M, Chesnut R: The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. / Biologicals 2001, 29:271-76. CrossRef
  20. Sutter G, Wyatt LS, Foley PL: A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. / Vaccine 1994, 12:1032-040. CrossRef
  21. Stittelaar KJ, Wyatt LS, de Swart RL: Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. / J Virol 2000, 74:4236-243. CrossRef
  22. Hirsch VM, Fuerst TR, Sutter G: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques:effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. / J Virol 1996, 70:3741-752.
  23. Carroll MW, Overwijk WW, Chamberlain S: Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. / Vaccine 1997, 15:387-94. CrossRef
  24. Espenschied J, Lamont J, Longmate J: CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Modes. / J Immunol 2003, 170:3401-407.
  25. Rosenberg SA: Cancer vaccines based on the identification of the genes encoding cancer regression antigens. / Immunol Today 1997, 18:175-82. CrossRef
  26. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM: Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. / Nat Med 1998, 4:397-02. CrossRef
  27. Zavala F, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Esteban M: A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8 (+) T cells. / Virology 2001, 280:155-59. CrossRef
  28. Ramirez JC, Gherardi MM, Rodriguez D: Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. / J Virol 2000, 74:7651-655. CrossRef
  29. Wei J-, Huang Y-, Zhong D-, Kang L, Ishag H, Mao X, Cao R-, Zhou B, Chen P-: Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice. / Biochem Biophys Res Commun 2010, 96:787-92. CrossRef
  30. Ho CY: Lau Clara BS, Kim CF, Leung KN, Fung KP, Tse TF, Chan Helen HL, Chow Moses SS: Differential effect of Coriolus versicolor (Yunzhi) extract on cytokine production by murine lymphocytes in vitro. / Int Immunopharmacol 2004, 4:1549-557. CrossRef
  31. Stuart N: / Isaacs: Vaccinia Virus and Poxvirology: Methods and Protocols in Methods in Molecular Biology, vol. 269. Totowa, New Jersey: Humana Press Inc; 2004.
  32. Ding J, Lu Y, Chen Y: Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. / FEMS Immunol Med Microbiol 2000, 29:123-27. CrossRef
  33. Wu SC, Yu CH, Lin CW, Chu IM: The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. / Vaccine 2003, 21:2516-522. CrossRef
  34. Vrati S, Agarwal V, Malik P, Wani SA, Saini M: Molecular characterization of Indian isolate of Japanese encephalitis virus that shows an extended lag phase during growth. / J Gen Virol 1999, 80:1665-671.
  35. Hamano M, Lim CK, Takagi H, Sawabe K, Kuwayama M, Kishi N: Detection of antibodies to Japanese encephalitis virus in the wild boars in Hiroshima prefecture, Japan. / Epidemiol Infect 2007,135(6):974-77. CrossRef
  36. Kaur R, Vrati S: Development of a recombinant vaccine against Japanese encephalitis. / J Neurovirol 2003, 9:421-31.
  37. Lowenadler B, Lycke N, Svanholm C, Svennerholm AM, Krook K, Gidlund M: T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. / Mol Immunol 1992, 29:1185-190. CrossRef
  38. Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA: Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. / J Immunol 1994, 152:549-56.
  39. Cardin RD, Brooks JW, Sarawar SR, Doherty PC: Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. / J Exp Med 1996, 184:863-71. CrossRef
  40. Hauge S, Madhun A, Cox RJ, Haaheim LR: Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. / Clin Vaccine Immunol 2007, 14:978-83. CrossRef
  41. Farrar MA, Schreiber RD: The molecular cell biology of interferon-γ and its receptor. / Annu Rev Immunol 1993, 11:571-11. CrossRef
  42. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. / APMIS 1995, 103:161-79. CrossRef
  
• 作者单位：Fengjuan Wang (1)
  Xiuli Feng (1)
  Qisheng Zheng (2)
  Hongyan Hou (3)
  Ruibing Cao (1)
  Bin Zhou (1)
  Qingtao Liu (4)
  Xiaodong Liu (1)
  Ran Pang (1)
  Jin Zhao (1)
  Wenlei Deng (1)
  Puyan Chen (1)
  
  1. Key Laboratory of Animal Diseases Diagnosis and Immunology, Ministry of Agriculture, Nanjing Agricultural University, Nanjing, 210095, China
  2. National Veterinary Biological Medicine Engineering Research Center, Nanjing, 210014, People’s Republic of China
  3. Veterinary Office, Gansu Agriculture and Animal Husbandry Department, Lanzhou, 730000, People’s Republic of China
  4. Veterinary Medicine, Yangzhou University, Yangzhou, 225009, China
  
• ISSN：1743-422X

文摘

Epitope-based vaccination might play an important role in the protective immunity against Japanese encephalitis virus (JEV) infection. The purpose of the study is to evaluate the immune characteristics of recombinant MVA carrying multi-epitope gene of JEV (rMVA-mep). The synthetic gene containing critical epitopes (B-cell, CTL and Th) of JEV was cloned into the eukaryotic expression vector pGEM-K1L, and the rMVA-mep was prepared. BALB/c mice were immunized with different dosages of purified rMVA-mep and the immune responses were determined in the form of protective response against JEV, antibodies titers (IgG1 and IgG2a), spleen cell lymphocyte proliferation, and the levels of interferon-γ and interleukin-4 cytokines. The results showed that live rMVA-mep elicited strongly immune responses in dose-dependent manner, and the highest level of immune responses was observed from the groups immunized with 107 TCID50 rMVA-mep among the experimental three concentrations. There were almost no difference of cytokines and neutralizing antibody titers among 107 TCID50 rMVA-mep, recombinant ED3 and inactivated JEV vaccine. It was noteworthy that rMVA-mep vaccination potentiates the Th1 and Th2-type immune responses in dose-dependent manner, and was sufficient to protect the mice survival against lethal JEV challenge. These findings demonstrated that rMVA-mep can produce adequate humoral and cellular immune responses, and protection in mice, which suggested that rMVA-mep might be an attractive candidate vaccine for preventing JEV infection.